Full-Time
Quality Management System Manager
Quality & Digital Systems
Zeiss
1,001-5,000 employees
Corporate venture capital for deep-tech startups
No salary listed
Bengaluru, Karnataka, India
In Person
Bachelor's, Master's
 Biology & Biotech (1) |
|---|
Get referred to Zeiss
See people who can refer or advise you
- A bachelor's or master's degree in engineering, natural sciences, or a related field.
- Strong knowledge of ISO 13485, ISO 9001, MDSAP, and GxP requirements.
- Three to seven years of experience in Quality Management within regulated industries such as medical devices or pharma.
- Proven experience in QMS operations, audits, and compliance management.
- Three to five years of exposure to digital quality systems and eQMS platforms.
- Strong understanding of QMS frameworks and regulatory requirements.
- Solid knowledge of audit methodologies and CAPA lifecycle management.
- Hands-on experience with eQMS platforms such as TrackWise, Veeva, or Dot Compliance.
- Strong analytical, problem-solving, and data interpretation skills.
- Excellent stakeholder management and communication skills.
- Ability to operate effectively in global, cross-functional environments.
- Fluent English is required.
- Own and support the lifecycle management and continuous improvement of the QMS in alignment with global regulatory standards.
- Identify systemic process gaps and drive structured risk-based assessments.
- Lead and support implementation of corrective and preventive actions to ensure long-term compliance and process stability.
- Lead planning, coordination, and execution of internal and external audits using a risk-based audit strategy.
- Ensure structured preparation, documentation, and timely closure of audit findings.
- Strengthen audit readiness across regions and ensure consistent compliance performance.
- Lead preparation and analysis of QMS performance metrics for management review.
- Support execution of Management Review Meetings, including tracking resulting actions.
- Manage and govern Change Review Board processes, ensuring effective evaluation and controlled implementation of quality-relevant changes.
- Drive design, implementation, validation, and lifecycle management of digital quality systems, including eQMS and RIMS platforms.
- Ensure compliance with Computer System Validation principles and data integrity requirements.
- Enable digital transformation of QMS processes through harmonized system architecture and governance.
- Analyze quality data, audit outcomes, deviations, and KPIs to identify improvement opportunities.
- Lead and support cross-functional improvement initiatives across NC/CAPA, document control, complaints, and deviation management.
- Design and support QMS-related training programs across systems and processes.
- Provide expert guidance to stakeholders on regulatory and QMS requirements.
- Support engagement with notified bodies, certification bodies, and external auditors.
- Ensure structured preparation and execution of external inspections and audits.
- Lead Auditor certification.
- Three to five years of experience in Computer System Validation.
- German language proficiency.
ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$67.7M
Headquarters
Oberkochen, Germany
Founded
2001
Get referred to Zeiss
See people who can refer or advise you
Simplify's Take
What believers are saying
- ZEISS led Maculaser's May 2026 round for retinal laser therapy commercialization.
- ZEISS Ventures led SeeTrue's €2.2 million round on August 6, 2026.
- ZEISS launched ClearMind lenses and DuraVision Plus in January 2026, reinforcing optical leadership.
What critics are saying
- Carl Zeiss Meditec cut 2026 revenue 5.7% and targets 1,000 job reductions.
- ZEISS's 2026 restructuring threatens innovation velocity and employee morale through 2028/29.
- A prolonged MedTech slump or failed turnaround would weaken ZEISS Ventures' strategic value.
What makes Zeiss unique
- ZEISS Ventures pairs capital with ZEISS distribution, engineering, and ophthalmology channels.
- Its 2026 deals target eye health, imaging, and optoelectronics adjacencies.
- ZEISS brand credibility de-risks pilots for startups selling into regulated healthcare.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Company News
ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.
ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.
ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.
ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.
ZEISS Medical Technology has received approval from Mexico's COFEPRIS for two ophthalmic surgical devices: the ARTEVO 850 microscope and MICOR 700 lens removal device. Both technologies are compatible with ZEISS's latest cataract workflow systems. The ARTEVO 850 is a 3D heads-up ophthalmic microscope offering true colour imaging and a nearly 60% increase in depth of field. The MICOR 700 is the first handheld lens removal device with ultrasound-free operation, using ZEISS's non-ultrasonic lens extraction procedure to minimise risk to surrounding eye structures. The products will be showcased at the Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026. ZEISS Medical Technology generated revenue of €2,066.1 million in fiscal year 2023/24.